In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials with a broader group of patients, or as use of these product candidates becomes more widespread if they receive marketing approval, illnesses, injuries, discomforts and other AEs that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by participants
Tirzepatide is a dual agonist that activates both GLP-1 and GIP receptors, opening an additional pathway to influence metabolic function
In JC virus-infected glioblastoma cells, it is possible to find the same MDR feature
251 Research by Ising et al
Pharmacy delay is a few days
By modulating nerve signals in the body, gabapentin holds promise as a tool in managing sciatica discomfort